La Jolla soars on mixed Phase II GCS-100 results
This article was originally published in Scrip
Executive Summary
La Jolla Pharmaceuticals skyrocketed 62.4% to $17.70 per share in after-hours trading on 10 March in response to top-line Phase II results for GCS-100 in chronic kidney disease (CKD). The clinical trial data showed statistical significance for the lowest dose of the San Diego-based company's galectin-3 inhibitor, but not for the highest dose.